Journal Mobile Options
Table of Contents
Vol. 12, No. 2, 2009
Issue release date: November 2008
Public Health Genomics 2009;12:112–120

Canada: Public Health Genomics

Little J. · Potter B. · Allanson J. · Caulfield T. · Carroll J.C. · Wilson B.
Departments of aEpidemiology and Community Medicine and bGenetics, Children’s Hospital of Eastern Ontario and Department of Pediatrics, University of Ottawa, Ottawa, Ont., cHealth Law Institute, University of Alberta, Edmonton, Alta., dDepartment of Family & Community Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ont., Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Canada has a diverse population of 32 million people and a universal, publicly funded health care system provided through provincial and territorial health insurance plans. Public health activities are resourced at provincial/territorial level with strategic coordination from national bodies. Canada has one of the longest-standing genetics professional specialty organizations and is one of the few countries offering master’s level training designed specifically for genetic counselors. Prenatal screening is offered as part of routine clinical prenatal services with variable uptake. Surveillance of the effect of prenatal screening and diagnosis on the birth prevalence of congenital anomalies is limited by gaps and variations in surveillance systems. Newborn screening programs vary between provinces and territories in terms of organization and conditions screened for. The last decade has witnessed a four-fold increase in requests for genetic testing, especially for late onset diseases. Tests are performed in provincial laboratories or outside Canada. There is wide variation in participation in laboratory quality assurance schemes, and there are few regulatory frameworks in Canada that are directly relevant to genetics testing services or population genetics. Health technology assessment in Canada is conducted by a diverse range of organizations, several of which have produced reports related to genetics. Several large-scale population cohort studies are underway or planned, with initiatives to harmonize their conduct and the management of ethical issues, both within Canada and with similar projects in other countries.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Statistics Canada. Portrait of the Canadian Population in 2006, 2006 Census. Population and Dwelling Counts. Ottawa: Minister of Industry, 2007. Available from
  2. Statistics Canada. The Evolving Linguistic Portrait, 2006 Census. Ottawa: Minister of Industry, 2007. Available from
  3. Statistics Canada. Canada’s ethnocultural portrait: The changing mosaic. Available from, accessed September 15, 2007.
  4. Health Canada. Canada’s Health Care System. Ottawa: Ministry of Health, 2005. Available from
  5. Canadian Institute for Health Information. National Health Expenditure Trends, 1975–2007. Ottawa: CIHI, 2007. Available from
  6. Hey J: On the number of New World founders: a population genetic portrait of the peopling of the Americas. PLoS Biol 2005;3:e193.
  7. Statistics Canada. Census 2006. Aboriginal peoples. Ottawa, Statistics Canada. Available from, accessed March 11, 2008.
  8. Young TK, Reading J, Elias B, O’Neil JD: Type 2 diabetes mellitus in Canada’s first nations: status of an epidemic in progress. CMAJ 2000;163:561–566.
  9. Pollex RL, Hanley AJ, Zinman B, Harris SB, Hegele RA: Clinical and genetic associations with hypertriglyceridemic waist in a Canadian aboriginal population. Int J Obes (Lond) 2006;30:484–491.
  10. Arbour L, Field L, Ross P, Erikson A, Yoshida E: The mystery of primary biliary cirrhosis in British Columbia’s First Nations people. Int J Circumpolar Health 2004;63(suppl 2):185–188.
  11. Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, Mitchell GA: Population history and its impact on medical genetics in Quebec. Clin Genet 2005;68:287–301.
  12. UNESCO. World Heritage List. L’Anse aux Meadows National Historic Site. UNESCO. Available from, accessed March 10, 2008.
  13. Ebermann I, Lopez I, Bitner-Glindzicz M, Brown C, Koenekoop RK, Bolz HJ: Deafblindness in French Canadians from Quebec: a predominant founder mutation in the USH1C gene provides the first genetic link with the Acadian population. Genome Biol 2007;8:R47.
  14. Lavoie EM, Tremblay M, Houde L, Vezina H: Demogenetic study of three populations within a region with strong founder effects. Community Genet 2005;8:152–160.
  15. Engert JC, Lemire M, Faith J, Brisson D, Fujiwara TM, Roslin NM, Brewer CG, Montpetit A, Darmond-Zwaig C, Renaud Y, Dore C, Bailey SD, Verner A, Tremblay G, St-Pierre J, Betard C, Platko J, Rioux JD, Morgan K, Hudson TJ, Gaudet D: Identification of a chromosome 8p locus for early-onset coronary heart disease in a French Canadian population. Eur J Hum Genet 2008;16:105–114.
  16. Rahman P, Jones A, Curtis J, Bartlett S, Peddle L, Fernandez BA, Freimer NB: The Newfoundland population: a unique resource for genetic investigation of complex diseases. Hum Mol Genet 2003;12(spec no 2):R167–R172.
  17. Green RC, Green JS, Buehler SK, Robb JD, Daftary D, Gallinger S, McLaughlin JR, Parfrey PS, Younghusband HB: Very high incidence of familial colorectal cancer in Newfoundland: a comparison with Ontario and 13 other population-based studies. Fam Cancer 2007;6:53–62.
  18. Olsen CL: The demography of colony fission from 1878–1970 among the Hutterites of North America. Am Anthropol 1987;89:823–837.
  19. Dawson DV, Ober C, Kostyu DD: Extended HLA profile of an inbred isolate: the Schmiedeleut Hutterites of South Dakota. Genet Epidemiol 1995;12:47–62.
  20. Glass HC, Boycott KM, Adams C, Barlow K, Scott JM, Chudley AE, Fujiwara TM, Morgan K, Wirrell E, McLeod DR: Autosomal recessive cerebellar hypoplasia in the Hutterite population. Dev Med Child Neurol 2005;47:691–695.
  21. Aksamit N: Heavy with history. The Forum, 1999. Available from http://www., accessed March 12, 2008.
  22. Statistics Canada. Religions in Canada. Overview: Canada still predominantly Roman Catholic and Protestant. Analysis Series 96F0030XIE2001015. Ottawa, Statistics Canada, 2003. Available from, accessed March 12, 2008.
  23. Bowen P: Workshop on genetic disorders in the Hutterites – Edmonton, Canada, October 12–13, 1983. Am J Med Genet 1985;22:449–451.
  24. Lalonde M: A New Perspective on the Health of Canadians: a working document. Minister of Supply and Services Canada, 1974. Available from
  25. Epp J: Achieving health for all: a framework for health promotion. Can J Public Health 1986;77:393–424.
  26. Ottawa charter for health promotion. Can J Public Health 1986;77:425–430.
  27. Federal, Provincial and Territorial Advisory Committee on Population Health. Strategies for Population Health. Investing in the Health of Canadians. Ottawa, Minister of Supply and Services Canada, 1994.
  28. Evans RG, Barer ML, Marmor TR: Why Are Some People Healthy and Others Not? The Determinants of Health of Populations. Piscataway, Aldine Transaction, 1994.
  29. Frank JW: Why ‘population health’? Can J Public Health 1995;86:162–164.
  30. Health Canada. Learning from SARS – Renewal of Public Health in Canada. Ottawa, Health Canada, 2004–11–08. Available from
  31. House of Commons of Canada. Government of Canada. Bill C-5. An Act Respecting the Establishment of the Public Health Agency of Canada and Amending Certain Acts, 2006. Available from, accessed March 15, 2008.
  32. Medlar B, Mowat D, Di Ruggiero E, Frank J: Introducing the National Collaborating Centres for Public Health. CMAJ 2006;175:493–494.
  33. The Pan-Canadian Public Health Network: Partners in Public Health. Available from, accessed May 27, 2008.
  34. McMillan C, Nagpal S: The public health system in Canada: not meeting the needs of Canadians. Healthc Pap 2007;7:60–65.
  35. Chambers LW, Sullivan SM: Reflections on Canada’s public health enterprise in the 21st century. Healthc Pap 2007;7:22–30.
  36. Mowat DL, Butler-Jones D: Public health in Canada: a difficult history. Healthc Pap 2007;7:31–36.
  37. Lozon JC, Alikhan LM: Canada’s public health system: is the pace of progress sufficient? Healthc Pap 2007;7:52–59.
  38. Deber R, McDougall C, Wilson K: Public health through a different lens. Healthc Pap 2007;7:66–71.
  39. Integrated Strategy on Healthy Living and Chronic Disease. Public Health Agency of Canada. Available from, accessed May 27, 2008.
  40. National Advisory Committee on Immunization. Canadian Immunization Guide, ed 7. Ottawa, Public Health Agency of Canada, 2006. Available from, accessed May 27, 2008.
  41. Health Canada, Office of the Chief Dental Officer Projects: The status of water fluoridation in Canada. Ottawa, Health Canada. Available from, accessed March 11, 2008.
  42. Chiarelli AM, Halapy E, Nadalin V, Shumak R, O’Malley F, Mai V: Performance measures from 10 years of breast screening in the Ontario Breast Screening Program, 1990/91 to 2000. Eur J Cancer Prev 2006;15:34–42.
  43. National Cancer Institute of Canada. Progress in cancer control: Screening. National Cancer Institute of Canada, 2006. Available from,3621,84658243_85787780_933832352_langId-en,00.html, accessed March 11, 2008.
  44. Treasury Board of Canada. Tabling of the 2007–08 Supplementary Estimates (A). 2007. Available from http://www.tbs-, accessed March 11, 2008.
  45. Sewitch MJ, Fournier C, Ciampi A, Dyachenko A: Adherence to colorectal cancer screening guidelines in Canada. BMC Gastroenterol 2007;7:39.
  46. National Committee on Colorectal Cancer Screening. Recommendations for population-based colorectal cancer screening. Public Health Agency of Canada, 2002. Available from, accessed August 31, 2005.
  47. Cancer Care Ontario. Colorectal Cancer Screening Program – Information for Health Care Providers. Available from, accessed September 2, 2007.
  48. Alberta Cancer Board. The Alberta Colorectal Cancer Screening Program. Available from, accessed September 2, 2007.
  49. Cancer Care Manitoba. Manitoba Colorectal Cancer Screening Program. Available from, accessed September 2, 2007.
  50. Colorectal Cancer Association of Canada. Colorectal Cancer – Nova Scotia. Available from, accessed September 2, 2007.
  51. Public Health Agency of Canada. Report on Plans and Priorities, 2006–2007. Ottawa, Treasury Board of Canada, 2006. Available from, accessed May 26, 2008.
  52. Genome-based Research and Population Health International Network (GRaPH Int). Montreal, Public Health Agency of Canada, 2008. Available from, accessed May 26, 2008.
  53. Permaul-Woods JA, Carroll JC, Reid AJ, Woodward CA, Ryan G, Domb S, Arbitman S, Fallis B, Kilthei J: Going the distance: the influence of practice location on the Ontario Maternal Serum Screening Program. CMAJ 1999;161:381–385.
  54. Carroll JC, Brown JB, Reid AJ, Pugh P: Women’s experience of maternal serum screening. Can Fam Physician 2000;46:614–620.
  55. Cavanagh J, Mathews M, Crane J: Awareness and use of maternal serum screening among women from the St. John’s region of Newfoundland and Labrador. J Obstet Gynaecol Can 2007;29:630–634.
  56. Summers AM, Langlois S, Wyatt P, Wilson RD, Society of Obstetricians and Gynaecologists of Canada: Prenatal screening for fetal aneuploidy. J Obstet Gynaecol Can 2007;29:146–179.
  57. Grant R, Flint K: Prenatal screening for fetal aneuploidy: a commentary by the Canadian Down Syndrome Society. J Obstet Gynaecol Can 2007;29:580–582.
  58. Potter B, O’Reilly N, Etchegary H, Graham I, Howley H, Walker M, Coyle D, Chorny Y, Cappelli M, Boland I, Wilson B: Exploring informed choice in the context of prenatal testing: findings from a qualitative study. Health Expectations, under review
  59. Paquette D, Lowry RB, Sauve R: Two to three percent of infants are born with a congenital anomaly, but who’s counting? A national survey of congenital anomalies surveillance in Canada. Chronic Dis Can 2006;27:36–38.
  60. Therrell BL, Adams J: Newborn screening in North America. J Inherit Metab Dis 2007;30:447–465.
  61. Hanley WB: Newborn screening in Canada – are we out of step? Paediatr Child Health 2005;10:203–207.
  62. National Newborn Screening and Genetics Resource Center. 2007. Available from, accessed March 27, 2008.
  63. Prasad C, Johnson JP, Bonnefont JP, Dilling LA, Innes AM, Haworth JC, Beischel L, Thuillier L, Prip-Buus C, Singal R, Thompson JR, Prasad AN, Buist N, Greenberg CR: Hepatic carnitine palmitoyl transferase 1 (CPT1 A) deficiency in North American Hutterites (Canadian and American): evidence for a founder effect and results of a pilot study on a DNA-based newborn screening program. Mol Genet Metab 2001;73:55–63.
  64. Avard D, Vallance H, Greenberg C, Potter B: Newborn screening by tandem mass spectrometry: ethical and social issues. Can J Public Health 2007;98:284–286.
  65. Belle-Isle L: Genetic testing for late onset diseases: a population and public health perspective. Health Policy Res Bull 2001;1:11–12.
  66. Williams-Jones B: Private genetic testing in Canada: a summary. Health Law Rev 2001;9:10–13.
  67. Begleiter ML: Training for genetic counsellors. Nat Rev Genet 2002;3:557–561.
  68. Carroll JC, Reid AJ, Woodward CA, Permaul-Woods JA, Domb S, Ryan G, Arbitman S, Fallis B, Kilthei J: Ontario Maternal Serum Screening Program: practices, knowledge and opinions of health care providers. CMAJ 1997;156:775–784.
  69. Carroll JC, Brown JB, Blaine S, Glendon G, Pugh P, Medved W: Genetic susceptibility to cancer. Family physicians’ experience. Can Fam Physician 2003;49:45–52.
  70. Carroll JC, Cappelli M, Millier F, Wilson BJ, Grunfeld E, Peeters C, Hunter AGW, Gilpin C, Prakash P: Genetic services for hereditary breast/ovarian and colorectal cancers – physicians’ awareness, use and satisfaction. Community Genet 2008;11:43–51.
  71. Bottorff JL, Blaine S, Carroll JC, Esplen MJ, Evans J, Nicolson Klimek ML, Meschino W, Ritvo P: The educational needs and professional roles of Canadian physicians and nurses regarding genetic testing and adult onset hereditary disease. Community Genet 2005;8:80–87.
  72. Hunter A, Wright P, Cappelli M, Kasaboske A, Surh L: Physician knowledge and attitudes towards molecular genetic (DNA) testing of their patients. Clin Genet 1998;53:447–455.
  73. Canadian Directory of Genetic Support Groups. London Health Sciences Centre, 2008. Available from, accessed March 27, 2008.
  74. Canadian Organization for Rare Disorders. 2008. Available from, accessed March 27, 2008.
  75. Family Medicine Genetics Program. 2008. Available from, accessed March 27, 2008.
  76. Hailey DM: Health technology assessment in Canada: diversity and evolution. Med J Aust 2007;187:286–288.
  77. Blancquaert I: Managing partnerships and impact on decision-making: the example of health technology assessment in genetics. Community Genet 2006;9:27–33.
  78. Andermann A, Blancquaert I, Beauchamp S, Déry V: Revisiting Wilson and Jungner in the Genomic Age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317–319.
  79. McGahan L, Kakuma R, Ho C, Bassett K, Noorani HZ, Joyce J, Allanson J, Taylor S: BRCA1 and BRCA2 predictive genetic testing for breast and ovarian cancers: A systematic review of clinical evidence. Ottawa, Canadian Coordinating Office for Health Technology Assessment, 2006.
  80. Makni H, St-Hilaire C, Robb L, Larouche K, Blancquaert I: Spectrométrie de masse en tandem et dépistage néonatal des erreurs innées du métabolisme: rapport technique. Montréal, AETMIS, 2007.
  81. Tranchemontagne J, Boothroyd L, Blancquaert I: Contribution of BRCA1/2 Mutation Testing to Risk Assessment for Susceptibility to Breast and Ovarian Cancer. Montréal, AETMIS, 2006.
  82. Guo B: IHE Report: Screening Newborns for Cystic Fibrosis. Edmonton, Alberta, Institute of Health Economics, 2007. Available from, accessed May 27, 2008.
  83. Caulfield TA, Burgess MM, Williams-Jones B, Baily MA, Chadwick R, Cho M, Deber R, Fleising U, Flood C, Friedman J, Lank R, Owen T, Sproule J: Providing genetic testing through the private sector – A view from Canada. ISUMA: Can J Policy Res 2001;2:72–81.
  84. Giacomini M, Miller F, Browman G: Confronting the ‘gray zones’ of technology assessment: evaluating genetic testing services for public insurance coverage in Canada. Int J Technol Assess Health Care 2003;19:301–316.
  85. Yeo M: Biobank Research: The Conflict between Privacy and Access Made Explicit. Canadian Biotechnology Advisory Council, 2004. Available from$FILE/Research-2004_Yeo-Final_e.pdf, accessed May 23, 2008.
  86. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC: A common allele on chromosome 9 associated with coronary heart disease. Science 2007;316:1488–1491.
  87. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, Olschwang S, Chiang T, Crowdy E, Ferretti V, Laflamme P, Sundararajan S, Roumy S, Olivier JF, Robidoux F, Sladek R, Montpetit A, Campbell P, Bezieau S, O’Shea AM, Zogopoulos G, Cotterchio M, Newcomb P, McLaughlin J, Younghusband B, Green R, Green J, Porteous ME, Campbell H, Blanche H, Sahbatou M, Tubacher E, Bonaiti-Pellie C, Buecher B, Riboli E, Kury S, Chanock SJ, Potter J, Thomas G, Gallinger S, Hudson TJ, Dunlop MG: Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 2007;39:989–994.
  88. Frank J, Di Ruggiero E, McInnes RR, Kramer M, Gagnon F: Large life-course cohorts for characterizing genetic and environmental contributions: the need for more thoughtful designs. Epidemiology 2006;17:595–598.
  89. Swede H, Stone CL, Norwood AR: National population-based biobanks for genetic research. Genet Med 2007;9:141–149.
  90. Wen SW, Chen XK, Rodger M, White RR, Yang Q, Smith GN, Sigal RJ, Perkins SL, Walker MC: Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol 2008;198:45.e1–45.e7.
  91. Bryant H, Robson PJ, Ullman R, Friedenreich C, Dawe U: Population-based cohort development in Alberta, Canada: a feasibility study. Chronic Dis Can 2006;27:51–59.
  92. Ashbury FD, Kirsh VA, Kreiger N, Leatherdale ST, McLaughlin JR: An invitation to develop Ontario’s cancer research platform: report of the Ontario cancer cohort workshop. Chronic Dis Can 2006;27:94–97.
  93. CARTaGENE. 2008. Available from∼cartagene/index.php?lang =french, accessed May 23, 2008.
  94. Jin YP, Ostbye T, Feightner JW, Di Legge S, Hachinski V: Joint effect of stroke and APOE4 on dementia risk: the Canadian Study of Health and Aging. Neurology 2008;70:9–16.
  95. Canadian Longitudinal Study on Aging. 2007. Available from, accessed May 25, 2008.
  96. P3G. Public Population Project in Genomics. 2008. Available from, accessed May 23, 2008.
  97. Knoppers BM, Chadwick R: Human genetic research: emerging trends in ethics. Nat Rev Genet 2005;6:75–79.
  98. Knoppers BM: Biobanks: simplifying consent. Nat Rev Genet 2004;5:485.
  99. Knoppers BM: Biobanking: international norms. J Law Med Ethics 2005;33:7–14.
  100. Caulfield T: Biobanks and blanket consent: The proper place of the public perception and public good rationales. King’s Law J 2007;18:209–226.
  101. Caulfield T, Ries NM: Consent, privacy and confidentiality in longitudinal population health research: The Canadian legal context. Health Law J 2004(suppl 1):65.
  102. Tansey J, Burgess M: The foundations, applications and ethical dimensions of biobanks. W. Maurice Young Centre for Applied Ethics, University of British Columbia, 2004. Available from, accessed May 23, 2008.
  103. Sheremeta L: Population Biobanking in Canada: Ethical, Legal and Social Issues. Canadian Biotechnology Advisory Committee, 2003. Available from, accessed May 23, 2008.
  104. Auray-Blais C, Patenaude J: A biobank management model applicable to biomedical research. BMC Med Ethics 2006;7:E4.
  105. Melzer D, Hogarth S, Liddell K, Ling T, Sanderson S, Zimmern RL: Genetic tests for common diseases: new insights, old concerns. BMJ 2008;336:590–593.
  106. Kutz G: Nutrigenetic testing. Tests purchased from four web sites mislead consumers. Washington, D.C.: United States Government Accountability Office, 2006.
  107. Janssens AC, Gwinn M, Bradley LA, Oostra BA, van Duijn CM, Khoury MJ: A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet 2008;82:593–599.
  108. Canadian Agency for Drugs and Technologies in Health. Health Technology Analysis Exchange. Canadian Agency for Drugs and Technologies in Health, 2007. Available from, accessed March 27, 2008.
  109. Leeder J: Botched tests cast doubts on cancer screening. The Globe and Mail, 15 March 2008, 2008. Available from

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50